Equity · Healthcare
PCVX
Vaxcyte, Inc. · NasdaqGS
The line runs $47.18 on 20 May through $56.20 on 17 July, on a scale from $45 to $65. Days the market did not trade hold the previous close, flat.
The chart above plots the price of PCVX over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 40 sessions over that window: $47.18 on 20 May 2026 through $56.20 on 17 July 2026.
Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Aug 18, 2026
PCVX insider trades
Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.
Showing the 12 most recent of 16 compensation filings in this window. The figures above count all of them.
PCVX reported financials
PCVX reported net income of −$766.6M for the fiscal year ended 31 Dec 2025.
Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
PCVX earnings
no date announced in SEC filings yet
Reported figures & scheduled dates · SEC EDGAR filings
PCVX institutional holders
8 of the 45 institutional funds we track reported a PCVX position for the quarter ended 30 Jun 2026 — a combined $239.0M; the latest of those filings landed 14 Aug 2026.
Source: SEC EDGAR 13F filings
PCVX fails-to-deliver
On 23 Jul 2026, 266 shares of PCVX failed to deliver (about $15K).
Source: SEC fails-to-deliver (CNS) data
Congressional trades in PCVX
The most recent congressional trade disclosed in PCVX is a purchase by Gilbert Ray Cisneros, Jr. (house, CA), dated 13 May 2026.
Source: U.S. House of Representatives financial disclosures